20th Anniversary

20 years of clinical research in cardiology


 

Stick with randomization

Some have suggested that loosening the standards for evidence generation in medicine to include observational data, big data, artificial intelligence, and alternative trial strategies, such as Mendelian randomization and causal inference of nonrandomized data, might help drive new treatments to the clinic faster. To this, Dr. Nissen and Dr. Cannon offer an emphatic no.

“The idea that you can use big data or any kind of nonrandomized data to replace randomized control trials is a bad idea, and the reason is that nonrandomized data is often bad data,” Dr. Nissen said in an interview.

“I can’t count how many bad studies we’ve seen that were enormous in size, and where they tried to control the variables to balance it out, and they still get the wrong answer,” he added. “The bottom line is that observational data has failed us over and over again.”

Not to say that observational studies have no value, it’s just not for determining which treatments are most efficacious or safe, said Dr. Cannon. “If you want to identify markers of disease or risk factors, you can use observational data like data collected from wearables and screen for patients who, say, might be at high risk of dying of COVID-19. Or even more directly, you can use a heart rate and temperature monitor to identify people who are about to test positive for COVID-19.

“But the findings of observational analyses, no matter how much you try to control for confounding, are only ever going to be hypothesis generating. They can’t be used to say this biomarker causes death from COVID or this blood thinner is better than that blood thinner.”

Concurring with this, the ESC, AHA, ACC, and WHF statement authors acknowledged the value of nonrandomized evidence in today’s big data, electronic world, but advocated for the “appropriate use of routine EHRs (i.e. ‘real-world’ data) within randomized trials, recognizing the huge potential of centrally or regionally held electronic health data for trial recruitment and follow-up, as well as to highlight the severe limitations of using observational analyses when the purpose is to draw causal inference about the risks and benefits of an intervention.”

Pages

Recommended Reading

Elevated PCSK9 levels associated with psoriasis suggest new treatment target
Federal Practitioner
CV deaths jumped in 2020, reflecting pandemic toll
Federal Practitioner
‘Ozempic face’: Accepting wrinkles for improved health
Federal Practitioner
Meta-analysis throws more shade aspirin’s way
Federal Practitioner
New ACC, AHA, SCAI interventional cardiology training guidance
Federal Practitioner
Bempedoic acid cuts CV events in statin-intolerant patients: CLEAR Outcomes
Federal Practitioner
COORDINATEd effort boosts optimal therapy in patients with T2D and ASCVD
Federal Practitioner
High CV risk factor burden in young adults a ‘smoldering’ crisis
Federal Practitioner
Keto/paleo diets ‘lower quality than others,’ and bad for planet
Federal Practitioner
Heart-healthy actions promote longer, disease-free life
Federal Practitioner